Analysts checked patients’ health-related quality of life after adding daratumumab to bortezomib and dexamethasone used to treat relapse/refractory multiple myeloma.
Investigators tested the utility of ultra-deep genomic testing to predict relapse in patients with myelodysplastic syndrome initiating conditioning therapy for allogeneic hematopoietic cell transplant (alloHCT).
Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.
A cost analysis shows daratumumab may be better used as a second-line treatment for transplant-ineligible patients with multiple myeloma.
Risk for disease progression or death increased for those with renal insufficiency in relapsed/refractory, newly diagnosed MM
Investigators compared elotuzumab plus lenalidomide, bortezomib, and dexamethasone (RVd) with RVd alone in the induction and maintenance therapy settings.
The National Comprehensive Cancer Network’s updated Clinical Practice Guidelines in Oncology for multiple myeloma newly include 3 new selinexor-containing regimens.
A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.
Study results suggest that the cost-effectiveness of daratumumab use may be lower with first- vs second-line therapy of transplant-ineligible multiple myeloma.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Several biomarkers were predictive of progression from smoldering MM to MM, according to a retrospective study.
The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
Combined with dexamethasone, melflufen may be efficacious among patients with heavily pretreated relapsed and refractory multiple myeloma.
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
For patients with relapsed or refractory multiple myeloma, subcutaneous bortezomib may improve the tolerability of combination panobinostat, bortezomib, and dexamethasone.
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
Idecabtagene vicleucel showed clinical benefit and no toxicity concerns in patients with relapsed and/or refractory multiple myeloma.
Age, high-risk disease, renal disease, and active or progressive disease were predictive of worse outcomes for patients with multiple myeloma and COVID-19.
Currently, interpretations of FDG-PET/CT findings within the context of treatment response have not been validated in the setting of multiple myeloma.
Intermittent dosing of the targeted agent may overcome toxicity limitations, providing a potential therapy for a hard-to-treat multiple myeloma.
In addition to age, sex, and comorbidities, a new study flagged uncontrolled cancer and renal insufficiency as key prognostic factors for COVID-19 outcomes.
Combination venetoclax, bortezomib, and dexamethasone may improve response rates among patients with relapsed/refractory MM with specific biomarkers.
A novel scoring system for patients with MM undergoing upfront autologous HSCT appears predictive of both progression-free survival and overall survival.
Adverse effect management and adherence strategies used to support patients with relapsed/refractory MM undergoing treatment on the STORM trial.
An analysis of outcomes for older patients with plasma cell myeloma suggests lenalidomide with bortezomib and dexamethasone is superior to doublet regimens.
Immunomodulatory imide drug (IMiD) therapy, including thalidomide and lenalidomide, has been associated with a high risk of VTE in patients with NDMM.
The triplet regimen resulted in an 18% reduction in risk for death.
The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.
Multiple myeloma trials appear to underrepresent racial minorities in enrollment and in reporting, with no obvious improvement in recent years.
The superiority of carfilzomib vs bortezomib in triplet therapy was compared in newly diagnosed multiple myeloma ineligible for immediate transplantation.
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
The cytogenetic abnormality was linked to inferior overall survival.
Patients with myeloma should receive 2 doses of the trivalent or quadrivalent vaccine influenza vaccine and vaccinations should continue annually.
The approval was based on data from the phase 3 CANDOR study and the phase 1b EQUULEUS trial.
Patients who relapsed 3 years or later after first transplant had significantly better progression-free and overall survival compared with those who relapsed earlier.
Increased odds of adverse outcomes seen for Hispanic/Latinos, African-American Blacks vs white patients.
A percentage of newly diagnosed patients had disease with lower genomic instability.
Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile.
The phase 3 IFM/DFCI 2009 trial investigators used WGS to determine genomic markers of long-term survival in patients with newly diagnosed MM.
The combination of carfilzomib, dexamethasone, and daratumumab significantly prolonged PFS in patients with relapsed or refractory multiple myeloma.
Patients with multiple myeloma on dialysis who are undergoing autologous stem cell transplantation are at an increased risk for inpatient mortality.
The FDA issued a clinical hold for a trial evaluating a universal CAR T-cell product in patients with relapsed or refractory multiple myeloma after 1 patient died.
MM cells expressing high levels of migration inhibitory factor may have poorer responses to proteasome inhibitors, resulting in adverse patient outcomes.
For patients with initial myeloma cast nephropathy, renal response rates did not significantly vary after doublet vs triplet bortezomib-based treatments.